Kyc-equivalent checks for trial participants legality

Introduction

KYC-equivalent checks for trial participants refer to identity-verification, eligibility-verification, and anti-fraud procedures used to establish that a person enrolling in a clinical or biomedical research trial is genuinely the individual represented in the research records. The expression is borrowed from the financial sector's Know Your Customer (KYC) framework, but clinical research operates under a different legal and ethical structure.

The legality of such checks depends on their purpose, necessity, proportionality, informed-consent requirements, privacy protections, data-security obligations, and applicable clinical-trial regulations. Researchers cannot automatically impose extensive identity checks merely because they are useful administratively.

The central legal challenge is to balance research integrity and participant protection against privacy, confidentiality, autonomy, and data-minimization principles.

Purpose of participant identity verification

Identity verification can serve legitimate research purposes. Sponsors and investigators may need to establish that:

the participant is a real individual;

the same person is not enrolled multiple times;

eligibility criteria are accurately documented;

informed consent is obtained from the correct individual;

safety information is correctly attributed;

trial payments or reimbursements reach the correct participant; and

clinical-trial records remain scientifically reliable.

Such objectives are particularly important in decentralized and technology-assisted trials, where recruitment and consent may occur remotely.

However, identity verification should be limited to information reasonably necessary for these purposes.

Difference between financial KYC and clinical-trial verification

Ordinary financial KYC is designed primarily to prevent money laundering, terrorist financing, fraud, and financial-system abuse. Clinical research has different objectives.

A trial investigator generally needs to establish participant identity and eligibility, not construct a comprehensive financial or behavioural profile.

Consequently, collecting extensive information such as financial history, unrelated biometric characteristics, social-media records, or unrelated government databases may be difficult to justify unless a specific legal or research purpose exists.

The appropriate principle is therefore KYC-equivalent verification, not unrestricted KYC transplantation.

Privacy and constitutional principles in India

The strongest constitutional foundation is Justice K.S. Puttaswamy (Retd.) v. Union of India (2017), where the Supreme Court of India recognized privacy as a fundamental right.

Privacy includes informational autonomy and protection against unjustified collection and use of personal information.

Clinical-trial participants may provide highly sensitive information concerning health, genetics, reproductive history, and biological characteristics. Identity-verification procedures should therefore satisfy legitimate-purpose and proportionality requirements.

A sponsor should be able to explain why a particular identifier is necessary and how the information will be stored, accessed, retained, and eventually deleted or anonymized.

Informed consent

Identity verification should also be appropriately disclosed to participants.

The general principle of informed consent requires participants to understand significant aspects of research participation, including relevant data processing.

The Supreme Court's reasoning concerning autonomy in Puttaswamy supports the proposition that individuals should exercise meaningful control over personal information.

In medical law, Montgomery v. Lanarkshire Health Board [2015] UKSC 11 emphasized patient autonomy and disclosure of material information. Although Montgomery concerned medical treatment rather than clinical-trial identity verification, its autonomy-based reasoning provides a useful analogy.

A participant should therefore not discover only after enrollment that extensive biometric or identity information is being retained for unrelated purposes.

Clinical-trial ethics and vulnerable participants

Clinical research involving vulnerable populations requires additional safeguards. Children, persons with impaired decision-making capacity, economically vulnerable individuals, and persons dependent upon medical institutions may require heightened protections.

Identity verification should never become a mechanism for coercion. Researchers should not condition participation on unnecessary disclosure of unrelated personal information.

The Declaration of Helsinki and internationally accepted research-ethics principles emphasize respect for participants, informed consent, privacy, and confidentiality.

Data minimization and purpose limitation

A legally defensible verification system should collect only information reasonably necessary to establish identity and trial eligibility.

For example, a trial may need a government-issued identifier or equivalent verification mechanism, but it does not automatically follow that the sponsor needs to retain a permanent copy of the entire identity document.

A stronger privacy model may distinguish between:

verification, where identity is confirmed;

recording, where limited information is retained; and

long-term storage, which requires an independent justification.

This distinction is particularly important when biometric identification is used.

Biometric verification

Biometric verification may provide stronger protection against duplicate enrollment, but it also creates additional privacy risks.

Facial recognition, fingerprints, iris scans, or other biometric identifiers are difficult to change if compromised. Their use should therefore be justified by the trial's requirements and applicable law.

In S. and Marper v. United Kingdom (ECtHR, 2008), the European Court of Human Rights recognized the privacy implications associated with retention of fingerprints and DNA profiles.

Although the case concerned law-enforcement databases, its reasoning demonstrates that biometric information cannot be treated as ordinary administrative information without considering privacy consequences.

Scientific integrity and duplicate enrollment

Identity verification can have a legitimate scientific function. Duplicate enrollment may distort clinical-trial results, particularly where the same participant appears to be several independent subjects.

Verification may therefore protect both participants and the scientific validity of the trial.

However, the method used should be proportionate. A sponsor should not collect more identifying information than necessary merely because duplicate enrollment is theoretically possible.

Data protection and cross-border trials

International clinical trials create additional legal complexity. A participant may be recruited in India, the sponsor may be located in another country, and trial data may be stored on cloud infrastructure elsewhere.

The Digital Personal Data Protection Act, 2023 and other applicable Indian requirements may become relevant to processing of digital personal data in India, while foreign data-protection regimes may apply depending on the trial structure.

The decision of the Court of Justice of the European Union in Data Protection Commissioner v. Facebook Ireland and Maximillian Schrems (Case C-311/18, 2020) demonstrates the importance of safeguards for international transfers of personal data.

Cross-border trial sponsors should therefore identify applicable jurisdictions before transferring participant identity information.

Regulatory accountability

Clinical-trial authorities may require reliable records demonstrating participant eligibility and consent. Regulators may inspect trial documentation to determine whether enrollment procedures were properly conducted.

In India, clinical research is governed through the applicable framework under the Drugs and Cosmetics Act, 1940, the New Drugs and Clinical Trials Rules, 2019, relevant Central Drugs Standard Control Organisation requirements, and applicable ethical standards.

An investigator's failure to maintain reliable participant records can compromise the integrity of the trial and potentially expose the institution or sponsor to regulatory consequences.

At the same time, regulatory compliance does not justify unnecessary collection. Verification systems should remain connected to a legally recognized research purpose.

Fraud prevention and participant payments

KYC-equivalent verification may also be relevant where participants receive compensation or reimbursement.

Verification can help ensure that payments are made to genuine participants and prevent fraudulent multiple enrollment.

However, financial verification should remain limited to what is necessary for payment administration. A clinical researcher should not automatically obtain extensive financial information simply because a participant receives compensation.

Judicial standards for legality

If a participant challenges an identity-verification requirement, courts may consider several questions:

Is the verification required by law or regulation?

What legitimate research purpose does it serve?

Is the information genuinely necessary?

Is there a less intrusive verification method?

Was the participant adequately informed?

Is the information securely stored?

Who can access it?

How long will it be retained?

Is it transferred to third parties or foreign jurisdictions?

Does the procedure discriminate against particular participants?

These questions reflect proportionality and privacy principles rather than treating KYC as an unlimited regulatory power.

Core principles

A legally defensible KYC-equivalent framework for trial participants should follow:

Purpose limitation: collect information only for legitimate trial purposes.

Necessity: verify identity only to the extent reasonably required.

Transparency: disclose verification procedures to participants.

Data minimization: avoid unnecessary identity information.

Security: protect identifiers and biometric information.

Limited retention: retain verification records only as legally or scientifically necessary.

Non-discrimination: ensure verification does not unjustifiably exclude participants.

Independent oversight: subject procedures to ethics and regulatory review.

Conclusion

KYC-equivalent checks for clinical-trial participants can be legally legitimate when they are used to ensure identity, eligibility, informed consent, participant safety, payment integrity, and scientific reliability. However, clinical research does not automatically inherit the broad scope of financial-sector KYC requirements.

The principles in Puttaswamy, Montgomery, S. and Marper, and Schrems II support a framework based on privacy, autonomy, proportionality, and secure handling of sensitive information. Indian clinical-trial legislation and ethical requirements provide the regulatory context.

The central principle is that participant identity may need to be verified, but verification should not become an unrestricted collection of personal information. A lawful system should collect only what is necessary, clearly explain its purpose, protect confidentiality, restrict secondary use, and provide appropriate safeguards for vulnerable research participants.